Game-Changing Launch: "Olivia" Health App The more significant driver of Tempus' rally was the announcement of its new AI-enabled health app, Olivia. Designed as a personal health concierge ...

Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry ...

Tempus AI announced a collaboration with the Institute for Follicular Lymphoma Innovation. The goal of the collaboration is to advance targeted therapy development for follicular lymphoma by ...

Tempus is expected to releases its 2024 fiscal-year fourth-quarter earnings report after the market closes. Analysts estimate a loss per share of 20 cents and revenue of $203.12 million. Get 5 ...

CHICAGO, February 18, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the ...

In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other stocks. The stock market may have registered losses on Friday, but remained firmer on a ...

In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other AI stocks. In a recent discussion at CNBC’s ‘Squawk on the Street’, NYU professor ...

In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other large-cap stocks. We previously covered 10 Large-Cap Stocks Insiders Are Buying Recently.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular ...

Tempus AI, Inc. Class A (TEM – Research Report) received a Hold rating and price target from William Blair analyst Andrew Brackmann today. The company’s shares closed yesterday at $89.44 ...